Journal of American College of Cardiology Article Reports Fewer Repeat Procedures With Boston Scientific's TAXUS(R) Liberte(R) Stent

Authors identify important differences between drug-eluting stent brands NATICK, Mass., May 11 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today welcomed the publication of an article in the current edition of the Journal of American College of Cardiology (JACC) rev...

Impulse Dynamics Announces Pivotal Results at the American College of Cardiology Annual Meeting Late-Breaking Session

Long-Term Data Demonstrate The OPTIMIZER(R) System to be Safe and Effective ORLANDO, Fla., March 29 /PRNewswire/ -- Impulse Dynamics (U.S.A.) Inc. announced today findings from the FIX-HF-5 study of its OPTIMIZER System at the 58th Annual Scientific Session of the American College of Cardiol...

Atritech to Participate in Late-Breaking Clinical Trial Presentation at American College of Cardiology Meeting

MINNEAPOLIS, Feb. 19 /PRNewswire/ -- Atritech, Inc. announced the upcoming presentation of the PROTECT AF trial results comparing the WATCHMAN(R) Left Atrial Appendage (LAA) Closure Device to the current standard of care, warfarin therapy, in patients with non-valvular atrial fibrillation. Th...

American College of Cardiology and Center of Excellence for Simulation Research of Western Michigan University (CESR) Partner for in situ Simulation to Improve Team Communication and Door-to-Balloon (D2B) Time

WASHINGTON, BATTLE CREEK, Mich., and EVANSTON, Ill., Oct. 20 /PRNewswire/ -- The American College of Cardiology (ACC) and the Center of Excellence for Simulation Research (CESR) of Western Michigan University announced the launch of an educational and research partnership, using in situ simula...

Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008

Comprehensive Data Provide Initial Proof of Concept Across Multiple Applications in the Hospital Setting Poster Presentation Number: 2032 Presenting Author: Dr. Mark Chan MUNICH, Germany, Sept. 2 /PRNewswire/ -- Regado Biosciences, Inc. ...

TRANSCEND(TM) Trial Results Presented at European Society of Cardiology Congress and Published in The Lancet

Landmark ARB trial investigated Micardis(R) (telmisartan) against placebo in reducing the composite endpoint of cardiovascular death, myocardial infarction, stroke and hospitalization for congestive heart failure in ACE inhibitor intolerant high-risk patients receiving current standard of ca...

Boston Scientific Announces Schedule for European Society of Cardiology Congress 2008

Company to present data from landmark SYNTAX clinical trial NATICK, Mass., Aug. 26 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today announced the schedule of the Company's major events and press announcements at the European Society of Cardiology Congress 2008,...

Data Presented at Annual Meeting of Japanese Society of Interventional Cardiology Demonstrate OrbusNeich's Genous(TM) Bio-engineered R Stent(TM) Has Better Outcomes When Compared to Drug-Eluting Stents

HONG KONG, July 7 /PRNewswire/ -- OrbusNeich today announced that data presented recently at the 17th Annual Meeting of the Japanese Society of Interventional Cardiology demonstrate that the Genous Bio-engineered R stent has better outcomes when compared to drug-eluting stents. Presented by ...

ATHENA Clinical Results with Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress

BUENOS AIRES, Argentina, May 22 /PRNewswire-FirstCall/ -- On May 21, 2008 at the World Congress of Cardiology (WCC), the press conference entitled, "New Perspectives in Atrial Fibrillation Management" chaired by John Camm, Professor of Clinical Cardiology, St George's University of London, hig...

ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress

BUENOS AIRES, Argentina, May 21 /PRNewswire-FirstCall/ -- Today at the World Congress of Cardiology (WCC), the press conference entitled "New Perspectives in Atrial Fibrillation Management" chaired by John Camm, Professor of Clinical Cardiology, St George's University of London, highlighted th...

Boston Scientific Announces Schedule for European Society of Cardiology Congress 2007

NATICK, Mass., Aug. 29 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today announced the schedule of the Company's major events and press announcements at the European Society of Cardiology Congress 2007, which runs from September 1 to 5 in Vienna, Austria. The Company...

CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007

PALO ALTO, Calif., Aug. 22 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX ) announced today that eight abstracts, including a clinical trial update session on anti-arrhythmia data from the MERLIN TIMI-36 study, have been accepted for presentation at the European Society of Card...

Clinical Impact of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) is Subject of Symposium at 16th Annual Scientific Congress of Hong Kong College of Cardiology

HONG KONG, May 1 /PRNewswire/ -- The clinical impact of the first-ever pro-healing stent, OrbusNeich's Genous Bio-engineered R stent, is the subject of a symposium at next month's 16th Annual Scientific Congress of the Hong Kong College of Cardiology. Scheduled for May 3 at the Sheraton Hong...

Three Dimensional Visualization of Right Ventricle Provides Important Information for Treatment of Patients with Tetralogy of Fallot, According to a Study in The American Journal of Cardiology

Model Created Using Piecewise Smooth Subdivision Surface Provides Both Shape and Volumetric Evaluation of Tetralogy of Fallot Patients SEATTLE, April 8, 2008 /PRNewswire/ -- Three dimensional visualization of the right ventricle provides important shape and volumetric insights that help ca...

Presentations at American College of Cardiology Meeting Highlight New Opportunities for HDL Therapy

Intravascular Ultrasound Demonstrates Utility in Evaluating Drug Efficacy; Dr. H. Bryan Brewer, Jr. Sees Enormous Potential for HDL Therapy PLEASANTON, CA, Mar 30, 2007 (MARKET WIRE via COMTEX News Network) -- Lipid Sciences, Inc. (NASDAQ: LIPD) Dr. H. Bryan Brewer, Jr., Chief Scientific Direct...

Portola Pharmaceuticals Presents Positive Phase I Data of Its ADP Receptor Antagonist at the American College of Cardiology

NEW ORLEANS, March 28, 2007 /PRNewswire/ -- Portola Pharmaceuticals, Inc. presented Phase I data of its ADP receptor antagonist at the of Cardiology's (ACC) 56th Annual Scientific Session this week. Portola's reversible antiplatelet compound, PRT060128, appeared safe and well-tolerated in this stu...

Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology

NATICK, Mass., June 04, 2007 /PRNewswire-FirstCall/ -- Boston Scientific Corporation today welcomed the publication of an article in the Journal of of Cardiology (JACC) reviewing the TAXUS ATLAS clinical trial, which evaluates the Company's second-generation TAXUS(R) Liberte(TM)(1) paclitaxel-elut...

Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in Journal of American College of Cardiology

SAN CARLOS, Calif., June 19, 2007 /PRNewswire-FirstCall/ -- Nuvelo, Inc. today announced the publication of the Phase 2 proof-of-concept data from the Anthem (Anticoagulation with rNAPc2 To Help Eliminate MACE)/TIMI 32 clinical trial (N=255) in the June 26th issue of the Journal of of Cardiology (...

Positive Aggrastat Results Featured in the Journal of the American College of Cardiology

Protocol for New Aggrastat Study in American Heart Journal WINNIPEG, Manitoba - (July 11, 2007) Medicure Inc. (TSX:MPH; Amex:MCU), a cardiovascular focused, biopharmaceutical company, today announced that the two-year, follow-up results from the STRATEGY (Single High-Dose Bolus Tirofiban and S...

2,500 Cases Completed With the Magnetic Irrigated Catheter

...tained the safety profile for which it has become well known." About Stereotaxis Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. T...

Montefiore Medical Center and Albert Einstein College of Medicine Herald New Agreement To Continue Forty-Plus Year Historic Relationship

...ion with New York Medical College for residency programs at the North Division. Distinguished centers of excellence at Montefiore include cardiology and cardiac surgery , cancer care , tissue and organ transplantation, children's health , women's health , surgery and the surgical subspe...

Correction to Earlier Release From Jewish Hospital and University of Louisville

...nd Women's Hospital in Boston. Following the press conference Roberto Bolli, Jewish Hospital Heart and Lung Institute Distinguished Chair in cardiology and Director of UofL's Institute for Molecular Cardiology, stated, "Another clinical trial is being conducted at another facility. The difference bet...

World's First Cardiac Adult Stem Cell Patient Receives Infusion

... Director and Chief of Invasive and Interventional cardiology at Jewish Hospital. Study leader Roberto...al Heart and Lung Institute Distinguished Chair in cardiology and Director of UofL's Institute for Molecular cardiology said, "We continue to enroll patients in this firs...

Injection Reverses Heart-Attack Damage

...Kuhn, M.D., and Kevin Bersell of the Department of cardiology at Children's, were able to restart the cell cycle...g Investigator Award, from the American College of cardiology in 2007. The study was funded by the Department of cardiology at Children's Hospital Boston, the Charles Hood Fo...

Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily

... under the brand name ADCIRCA(TM). "PAH is a rare, life-threatening disease," said lead investigator Dr. Nazzareno Galie, Associate Professor of cardiology at the University of Bologna and head of the Pulmonary Hypertension Centre at the Institute of Cardiology. "The results of this study are encouraging ...

SCAI Statement on the BARI 2D Trial (Bypass Angioplasty Revascularization Investigation With Diabetes Trial) Presented at the American Diabetes Association (ADA) Annual Scientific Sessions and Published in The New England Journal of Medicine

...lation," said Steven R. Bailey, SCAI President and Chief of the Division of cardiology at the University of Texas Health Sciences Center at San Antonio. "Unfor...tients," said Steven R. Bailey, SCAI President and Chief of the Division of cardiology at the University of Texas Health Sciences Center at San Antonio. "No on...

vProtect(TM) Luminal Shield Stabilizes Vulnerable Plaque

...am. The 6-month follow-up exam was performed on May 20 by an interventional cardiology team led by Professor Patrick Serruys, the principal investigator for the S...hodology can be found in a case study published recently in Nature Reviews cardiology (vol. 6, May 2009). The follow-up exam indicated that the self-expan...

Results and Additional Analyses From Study Show That Corthera's Relaxin for Acute Heart Failure is the Strongest Predictor of Improved Longer-Term Outcomes Following Hospital Discharge When Compared to Other Variables

...presented today by Marco Metra, M.D., professor of cardiology at the University of Brescia, Italy, and co-princi...art Failure Association of the European Society of cardiology (HFA-ESC 2009) in Nice, France. Several variab... Ponikowski, M.D., Ph.D, head of the department of cardiology at the Clinical Military Hospital in Wroclaw, Pola...

Results and Additional Analyses From Efficacy and Safety Study of Corthera's Relaxin in Acute Heart Failure to be Presented at Heart Failure Congress 2009

... annual meeting of the Heart Failure Association of the European Society of cardiology in Nice, France. Marco Metra, M.D., professor of cardiology at the University of Brescia, Italy, and co-principal investigator of the P...

Long Term Data Presented at EuroPCR 2009 from Randomized Study Attest to Durability of Results of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) Compared to Drug-Eluting Stents

...n Hong Kong and has operations in Fort Lauderdale, FL; Hoevelaken, The Netherlands; Tokyo, Japan; and Shenzhen, China. OrbusNeich, which has provided cardiology devices to physicians through its predecessor companies since 1979, today supplies products to interventional cardiologists in more than 60 countries....

Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results

...hypertension/jnc7full.pdf . Accessed April 16, 2009. (8) European Society of Hypertension. European Society of Hypertension-European Society of cardiology 2007 Guidelines for the Management of Arterial Hypertension. Available at: http://www.eshonline.org/pdf/2007_esh_esc_guidelines.pdf . Accessed Ap...

InspireMD Announces the Enrollment of the 1st Patient in the MGuard iMOS Registry, the Registry Will Enroll 1000 Patients

...ization of its proprietary stent system technology, MGuard(TM). The company intends to apply its technology to develop products used in interventional cardiology and other vascular procedures. InspireMD's mission is to utilize its proprietary technology to make its products the industry standard for stents and ...

Video: ev3 Inc. Announces First Patient Enrollments in DEFINITIVE LE Post-Market Study

...D using plaque excision in both above- and below-the-knee applications," said co-principal investigator Lawrence Garcia, M.D., Chief of Interventional cardiology and Associate Director of Vascular Medicine at St. Elizabeth's Medical Center, Boston. "Furthermore, this study will potentially add new insight on th...

Corgenix AspirinWorks(R) Test Recognized in POLYCAP Study at ACC.09

.... Results of the randomized, controlled, double-blind study were presented as a late breaking clinical trial March 30 at the American College of cardiology (ACC) 58th Annual Scientific Sessions in Orlando, Fla. Corgenix is exhibiting its test in Booth No. 1162 during ACC.09. Overall results showed th...

Schering-Plough Announces Results of the Early ACS Trial

... KENILWORTH, N.J., March 30 /PRNewswire-FirstCall/ -- In a study presented today at the 58th annual Scientific Sessions of the American College of cardiology and simultaneously published by The New England Journal of Medicine, researchers reported that a strategy using an upstream, investigational dose of I...

New Data for Abbott's TRILIPIX(R) (fenofibric acid) in Combination with Rosuvastatin Calcium Shows Improvement on Key Lipids for Cholesterol Management

...re at recommended levels for all three key lipids. Treatment guidelines endorsed by the National Cholesterol Education Panel, the American College of cardiology and the American Heart Association have called for more aggressive management of lipids, including a lower LDL goal for many patients, as well as more...

CRESTOR(R) Reduced Risk of Blood Clots in the Veins

... cholesterol levels and elevated high-sensitivity C-reactive protein (hsCRP). This analysis was presented today at the 58th Annual American College of cardiology Scientific Sessions (ACC) in Orlando, Florida, and published simultaneously in the New England Journal of Medicine. Venous thromboembolism, a s...

Results From Study Show Promising Efficacy and Safety Results for Corthera's Relaxin in Acute Heart Failure

...in administration was safe and well tolerated. These results provide a clear direction for the Phase III study." Marco Metra, M.D., professor of cardiology at the University of Brescia, Italy, and co-principal investigator of the study, added: "There has been an epidemic of hospitalization for heart failu...

Abbott's Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years

... XIENCE V demonstrated a consistent reduction compared to TAXUS out to three years," said Patrick W. Serruys, M.D., Ph.D., professor of Interventional cardiology at Thoraxcentre, Erasmus University Hospital, Rotterdam, the Netherlands, and principal investigator of the SPIRIT II clinical trial. "What's even m...

MitraClip(R) Therapy Data Shows Important Clinical Benefit in High Risk Patients With Functional Mitral Regurgitation at 12-Month Follow Up

...f the EVEREST II (Endovascular Valve Edge-to-Edge REpair STudy) study presented today at the 58th Annual Scientific Session of the American College of cardiology (ACC) i2 Summit Scientific Sessions. As the most common type of heart valve disease, MR affects more than four million people in the United Stat...